Welcome to our dedicated page for Amylyx Pharmaceuticals SEC filings (Ticker: AMLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking clinical-stage biotech disclosures can feel like decoding lab notes. Amylyx Pharmaceuticals鈥� SEC documents are packed with trial endpoints, FDA correspondence, and detailed R&D spend鈥攙ital but time-consuming data to locate. If you have ever searched 鈥淎mylyx Pharmaceuticals SEC filings explained simply鈥� or wondered whether fresh Form 4 insider transactions hint at confidence before pivotal ALS results, you know the challenge.
Stock Titan solves it. Our AI instantly summarizes every Amylyx Pharmaceuticals annual report 10-K simplified and each quarterly earnings report 10-Q filing, spotlighting cash runway, pipeline updates, and revenue guidance. AG真人官方-time alerts flag new Amylyx Pharmaceuticals Form 4 insider transactions real-time, while intuitive dashboards connect numbers to narrative鈥攏o more scanning hundreds of pages for one clinical milestone.
Need specifics? Open an 8-K material events explained card to see why management issued the notice or jump to the proxy statement executive compensation section to compare pay against trial progress. Our platform links:
- Amylyx Pharmaceuticals insider trading Form 4 transactions
- Amylyx Pharmaceuticals earnings report filing analysis
- Understanding Amylyx Pharmaceuticals SEC documents with AI
Whether you monitor executive stock transactions Form 4 for sentiment shifts or evaluate safety data in 10-Qs, Stock Titan鈥檚 AI-powered summaries, expert context, and EDGAR-speed updates keep you ahead鈥攕o you can focus on decisions, not document hunts.
Amylyx is advancing multiple clinical-stage programs with clear near-term catalysts. In April 2025 the company dosed the first participant in LUCIDITY, a pivotal Phase 3, randomized, double-blind, placebo-controlled 16-week trial of avexitide in post-RYGB post-bariatric hypoglycemia (PBH). Approximately 75 participants will be randomized 3:2 to 90 mg once daily or placebo; completers may enter a 32-week open-label extension. Recruitment is expected to finish in 2025 with topline data in H1 2026 and a potential commercial launch in 2027 if approved. Avexitide holds FDA Breakthrough Therapy, Rare Pediatric Disease and Orphan Drug designations for hyperinsulinemic hypoglycemia indications. Separately, AMX0035 showed sustained pancreatic function improvements through Week 48 in a Phase 2 Wolfram syndrome study and will inform Phase 3 planning. AMX0114 initiated first dosing in April 2025 in the Phase 1 LUMINA ALS trial (鈮�48 participants randomized 3:1; intrathecal dosing every 4 weeks up to four doses) with early cohort data expected in 2025. The prospectus notes proceeds will fund avexitide commercial readiness, R&D and general corporate purposes.
Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals (AMLX), reported two Rule 10b5-1 sales totaling 30,000 common shares on August 12, 2025 and August 13, 2025. The August 12 sales comprised 15,000 shares at a weighted average price of $8.0735 (trades ranged $7.82鈥�$8.27) and the August 13 sales comprised 15,000 shares at a weighted average price of $8.3364 (trades ranged $8.13鈥�$8.47). After these transactions the reporting person beneficially owned 156,969 shares. The sales were executed under a 10b5-1 trading plan adopted on May 13, 2025. The Form 4 was filed and signed by an attorney in fact on August 14, 2025.
Amylyx Pharmaceuticals (AMLX) filed a Form 144 reporting a proposed sale of 30,000 common shares through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing lists an aggregate market value of $234,600, an approximate sale date of 08/12/2025, and that the shares trade on NASDAQ. The filing reports 89,167,432 shares outstanding, meaning the 30,000-share notice represents approximately 0.034% of outstanding shares.
The securities were acquired as Restricted Stock Units from the issuer on 09/30/2024 and paid on that date. The filing reports "Nothing to Report" for securities sold in the past three months. Some standard Form 144 attestation language about material nonpublic information and Rule 10b5-1 is present, while several filer and issuer identification fields in the form appear blank or not provided.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports shared beneficial ownership of 8,800,000 shares of Amylyx Pharmaceuticals, Inc. ("AMLX"). Those shares represent 9.87% of the company's common stock, based on an aggregate of 89,141,087 shares outstanding as of April 28, 2025. The holding is reported as shared voting and shared dispositive power of 8,800,000 shares, with 0 shares of sole voting or sole dispositive power.
The filing is submitted on Schedule 13G/A and includes a certification that the securities were acquired and are held in the ordinary course of business and not to influence control of the issuer.
Key disclosure: On 24 June 2025 Point72 Asset Management, Point72 Capital Advisors and founder Steven A. Cohen jointly filed a Schedule 13G regarding Amylyx Pharmaceuticals, Inc. (AMLX).
The filing shows 4,717,709 AMLX common shares held through Point72 Associates, equivalent to 5.3 % of the company鈥檚 outstanding stock. All voting and dispositive authority is listed as 鈥渟hared,鈥� with zero sole power reported. The report is passive, made under Rule 13d-1(b), and classifies the reporting persons as: Point72 Asset Management 鈥� 鈥淧N鈥� (Partnership), Point72 Capital Advisors 鈥� 鈥淐O鈥� (Corporation), and Mr. Cohen 鈥� 鈥淚N鈥� (Individual).
Ownership is indirect: Point72 Asset Management manages the securities, Point72 Capital Advisors is its general partner, and Mr. Cohen controls both entities. The principal business address for all parties is 72 Cummings Point Road, Stamford, CT 06902. A joint-filing agreement (Exhibit 99.1) formalises combined reporting.
This disclosure elevates Point72 to the roster of 鈮�5 % institutional holders of Amylyx, giving the hedge fund material visibility in the share register; however, the filing contains no purchase prices, transaction timetables, or stated strategic intentions beyond passive investment.
FAQ
What is the current stock price of Amylyx Pharmaceuticals (AMLX)?
What is the market cap of Amylyx Pharmaceuticals (AMLX)?
